Some patients may remain on 1.7 mg as a maintenance dose if the 2.4 mg dose is not tolerated
Results While GLP-1 and GIP agonists demonstrate significant metabolic benefits, their long-term use is often limited by gastrointestinal side effects and psychological impacts
Although DSM-5 diagnosis is defined through multiple behavioral criteria encompassing impaired control, social dysfunction, continued use despite harm, and tolerance or withdrawal, converging clinical and preclinical evidence indicates that the core pathological feature of SUDs is the progressive loss of control over intake (O'Brien, 2005)
For many people, semaglutide is better known as the injectable drug Ozempic
"Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism